Clinical Advances and New Insights in Systemic Sclerosis
A special issue of Sclerosis (ISSN 2813-3064).
Deadline for manuscript submissions: 20 December 2025 | Viewed by 422
Special Issue Editor
Interests: systemic sclerosis (scleroderma); fibrosis; inflammasome signaling; collagen export from the endoplasmic reticulum; small molecule therapeutic development
Special Issue Information
Dear Colleagues,
Systemic sclerosis (SSc), or scleroderma, is a rare autoimmune disease marked by widespread fibrosis of the skin and organs, vascular abnormalities, and immune dysregulation. Despite progress in our understanding of its mechanisms, effective treatments remain limited.
This Special Issue, "Clinical Advances and New Insights in Systemic Sclerosis", aims to highlight recent clinical breakthroughs, research developments, and emerging therapies for SSc. We invite submissions addressing early diagnosis, enhanced management, and patient-specific treatments, with the aim of offering a comprehensive overview of current and future SSc care. Submissions may cover a range of topics including, but not limited to, the following:
- Pathophysiology: The mechanisms driving fibrosis, immune dysfunction, and vascular changes.
- Early Diagnosis: New tools and biomarkers for the early detection of SSc.
- Clinical Subtypes: SSc phenotypes and personalized treatment strategies.
- Treatments: Advances in biologics, immunosuppression, and non-pharmacologic approaches.
- Long-Term Care: Managing complications and improving patient outcomes.
- Future Research: Novel therapies, biomarkers, and personalized medicine.
Dr. Carol M. Artlett
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Sclerosis is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- systemic sclerosis
- scleroderma
- fibrosis
- biomarkers
- personalized treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
